Yongli Dong

Yongli Dong currently serves as a Principal Scientist at AbbVie since October 2023 and holds the position of Associate Director/Principal Scientist at BlueRock Therapeutics since January 2021. In roles at BlueRock Therapeutics, Yongli has engineered iPSC-derived macrophages, developed humanized animal models, and led preclinical studies evaluating efficacy and safety for various immune-oncology and autoimmune therapies. Previous experience includes a Senior Scientist role at Astellas Pharma, where Yongli managed preclinical studies and investigated cellular product efficacy using rodent models. As a Scientist and Project Leader at Precigen Inc, Yongli worked on CAR-T cell development for autoimmune diseases. Yongli's academic background includes a long tenure at Yale University School of Medicine, focusing on cancer immunotherapy and T regulatory cell research, supported by a Ph.D. in Immunology from Fudan University.